OBI Pharma Inc (浩鼎生技) has signed an agreement with Odeon Therapeutics (Hong Kong) Ltd (康騰浩諾香港生物科技) to give it the rights to two of its experimental drugs, OBI-833 and OBI-999, in China, OBI said on Tuesday.
OBI would receive US$200 million for the licensing of the cancer drugs, which includes US$12 million in newly issued Odeon shares as a signing payment, and US$188 million as development and commercialization milestone payments, the Taipei-based company said in a regulatory filing.
The drug developer would also receive double-digit percentage royalties on Odeon’s net sales of the two drugs after they are approved in China, it said.
Photo: Chen Yung-chi, Taipei Times
OBI granted Odeon exclusive rights to further develop, register and commercialize OBI-999 and OBI-833, it said, adding that the deal also includes Hong Kong and Macau.
Odeon would be responsible for all development costs, as well as subsequent regulatory and commercialization costs, it added.
The Ministry of Economic Affairs’ Investment Commission has approved the deal, OBI said.
As China’s cancer treatment market has great potential for growth, OBI and Odeon are planning to press ahead with the research and sale of the two drugs, aiming to share the commercial benefits, the filing said.
OBI-833 and OBI-999 are experimental drugs targeting Globo H, a tumor antigen that has been detected in up to 15 different cancers and has been reported to play an important role in tumor progression.
OBI-833 is a therapeutic cancer vaccine consisting of a synthetic Globo H antigen, while OBI-999 is a novel antibody drug conjugate using a Globo H antibody to target cancer cells with high Globo H expression.
“Odeon looks forward to working closely with OBI to bring these new treatment options to patients in China,” OBI chief executive officer Tim Xiao (肖汀) said in a statement.
OBI-999 has completed phase 1 trials in the US, showing excellent safety and pharmacokinetics, while OBI-333 also demonstrated great potential as an immune-oncology therapeutic vaccine, Xiao said.
OBI said that it gained local approval to conduct phase 2 clinical trial for OBI-333, expecting primary endpoint evaluation in 2024.
After several years flying high as Asia’s best Nvidia Corp proxy, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is increasingly vying with other artificial intelligence (AI) stocks for investor attention. Stock traders are chasing a wider array of beneficiaries as mainstream usage of AI creates demand for hardware beyond the most-advanced chips TSMC makes for Nvidia. Subthemes from the deepening memory crunch to advances in robotics are also luring bids. At the same time, investment caps on single stocks are pushing funds to diversify, while retail investors long familiar with TSMC through its US depositary receipts are being offered a broader set of
Netherlands-based semiconductor equipment supplier ASML Holding NV yesterday said that it is planning to hire an additional 1,000 people in Taiwan this year in response to growing demand from clients. ASML had previously planned to recruit 600 people this year, but that the plan has been adjusted upward, ASML vice president and ASML Taiwan general manager Grace Wang (汪佳慧) told reporters. ASML has a workforce of more than 4,500 in Taiwan, accounting for about 10 percent of its global total, Wang said. This year’s recruitment campaign would focus on adding people in the customer support, manufacturing and supply chain domains to assist ASML
UNDER MICROSCOPE: Taiwan detained three people who allegedly conspired to buy servers in Taiwan and export them using fraudulent documentation, prosecutors said Nvidia Corp chief executive officer Jensen Huang (黃仁勳) on Saturday urged Super Micro Computer Inc to tighten up on compliance after Taiwan detained three people this week for allegedly making fraudulent declarations about artificial intelligence (AI) servers made by its US partner. The development marked the nation’s first crackdown on semiconductor smuggling, which grew after the US slapped restrictions on exports of high-end chips such as Nvidia AI accelerators to China. Nvidia is “rigorous” in explaining regulations to all of its partners, Huang told reporters after arriving in Taipei. “Ultimately Super Micro has to run their own company,” he said in response to
Nvidia Corp yesterday announced that CEO Jensen Huang (黃仁勳) would attend an employee meeting in Taipei tomorrow to celebrate the launch of the company’s Taiwan headquarters project. Huang would attend a gathering at the site of Nvidia’s planned headquarters in Beitou Shilin Technology Park (北投士林科技園區), the company said in a statement. After arriving in Taiwan on Saturday last week, Huang told reporters that he plans to meet with Quanta Computer Inc (廣達) chairman Barry Lam (林百里) and Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) chairman C.C. Wei (魏哲家), and would attend the groundbreaking ceremony for Nvidia’s Taiwan headquarters tomorrow. Nvidia has not yet applied
RSS